PT  - JOURNAL ARTICLE
AU  - Anzinger, Joshua J.
AU  - Cameron-McDermott, Suzette M.
AU  - Phillips, Yakima Z.R.
AU  - Mendoza, Leshawn
AU  - Anderson, Mark
AU  - Cloherty, Gavin
AU  - Strachan-Johnson, Susan
AU  - Lindo, John F.
AU  - Figueroa, J. Peter
TI  - Prevalence of SARS-CoV-2 Antibodies after the Omicron Surge, Kingston, Jamaica, 2022
AID  - 10.1101/2022.09.20.22280173
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.09.20.22280173
4099  - http://medrxiv.org/content/early/2022/09/21/2022.09.20.22280173.short
4100  - http://medrxiv.org/content/early/2022/09/21/2022.09.20.22280173.full
AB  - A cross-sectional SARS-CoV-2 serosurvey was conducted after the Omicron surge in Jamaica using 1,540 samples collected during March – May 2022 from persons attending antenatal, STI and non-communicable diseases clinics in Kingston, Jamaica. SARS-CoV-2 spike receptor binding domain (RBD) and/or nucleocapsid IgG antibodies were detected for 88.4% of the study population, with 77.0% showing evidence of previous SARS-CoV-2 infection. Of persons previously infected with SARS-CoV-2 and/or with COVID-19 vaccination, 9.6% were negative for spike RBD IgG, most of which were unvaccinated previously infected persons. Amongst unvaccinated previously infected people, age was associated with testing spike RBD IgG negative. When considering all samples, median spike RBD IgG levels were 131.6 BAU/mL for unvaccinated persons with serological evidence of past infection, 90.3 BAU/mL for vaccinated persons without serological evidence of past infection, and 896.1 BAU/mL for vaccinated persons with serological evidence of past infection. Our study of the first reported SARS-CoV-2 serosurvey in Jamaica shows extensive SARS-CoV-2 population immunity, identifies a substantial portion of the population lacking spike RBD IgG, and provides additional evidence for increasing COVID-19 vaccine coverage in Jamaica.Competing Interest StatementG. C. and M. A. are employees and shareholders of Abbott Laboratories. J.A. has received compensation from Abbott Laboratories.Funding StatementAbbott Laboratories provided tests required to perform this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ministry of Health and Wellness Ethics Committee of the Jamaican Ministry of Health and Wellness gave ethical approval for this work (2022/20).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors